---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-292706"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:58:07.493470+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IN8bio raises $14.4M in private placement; potential total up to $46.9M via warrant exercises

## Summary
- Initial gross proceeds of $14.4M from selling 11.8M units at $1.22/unit; extends cash runway into 2025.
- Investors get Series A warrants ($1.25 strike) exercisable upon INB-100 11-month data announcement for up to $14.8M additional.
- Series B warrants ($1.50 strike) redeemable upon 22-month data; potential $17.7M extra if all exercised.
- Pre-funded warrants at $0.0001 exercise price included; Cantor Fitzgerald acted as sole placement agent.
- Proceeds to fund clinical development of gamma-delta T cell therapies and general corporate purposes.

## SEC filing metadata
- accession: 0001193125-23-292706
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/d634758d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-292706
- JSON: https://secwatch.observer/filing/0001193125-23-292706.json
- Plain text: https://secwatch.observer/filing/0001193125-23-292706.txt

## Key facts
- Material Agreements
  IN8BIO, INC. entered into Securities Purchase Agreement with the purchasers named therein (the Investors) valued at $14.4 million (effective 2023-12-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein (the Investors)
  - Value: $14.4 million
  - Effective: 2023-12-11
  source text: On December 11, 2023, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of 11,823,829 units (the “Units”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm
- Material Agreements
  IN8BIO, INC. entered into Registration Rights Agreement with the Investors (effective 2023-12-11).
  - Action: entry
  - Counterparty: the Investors
  - Effective: 2023-12-11
  source text: Also on December 11, 2023, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Company agreed to register for resale the Shares and the Common Stock underlying the Warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312523292706/0001193125-23-292706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.